Latest / The Well-Built Life / Unlocking HIV Latency: New Protein Pathways Decoded
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:15Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:19Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:24Speaker 1: And let's dive in. So, we often hear about the
- 0:27Speaker 1: challenges in completely eradicating HIV, right? Despite the incredible progress
- 0:32Speaker 1: with antiretroviral therapy, the virus can lurk in dormant forms
- 0:36Speaker 1: even in patients receiving treatment. This new research, led by Dr.
- 0:41Speaker 1: Gochun Zhang and Dr. Waqas Ahmed at the University of
- 0:45Speaker 1: North Carolina, sheds light on exactly where and how that happens.
- 0:50Speaker 2: Right, and that's the crucial nuance here. It's not just
- 0:54Speaker 2: that the virus is hiding, it's maintaining itself in an
- 0:57Speaker 2: almost permanent state of latency. That's what makes it so
- 1:01Speaker 2: tricky to eliminate. So, could you walk us through what Dr.
- 1:05Speaker 2: Jiang and Dr. Ahmed specifically found?
- 1:07Speaker 1: Exactly, which brings up an interesting contradiction. They identified three
- 1:13Speaker 1: key proteins, ELL-USP7 and BRD4, that are crucial in maintaining
- 1:20Speaker 1: viral latency. ENL, in particular, is involved in enhancing the
- 1:25Speaker 1: role of BRD4, which stabilizes viral DNA, effectively keeping the
- 1:31Speaker 1: virus dormant. And USP7 is the one that disrupts this
- 1:36Speaker 1: equilibrium by destabilizing it.
- 1:38Speaker 2: Wait, but how does that actually play out in practice? So,
- 1:43Speaker 2: they are essentially looking at the biochemical pathways these proteins
- 1:47Speaker 2: use to keep the virus snoozing.
- 1:49Speaker 1: Precisely. And these findings are groundbreaking because they suggest new
- 1:53Speaker 1: avenues for targeting these mechanisms. For example, disrupting NLR-USP7 could
- 2:00Speaker 1: potentially reawaken HIV in both peripheral blood and brain immune cells.
- 2:05Speaker 1: This isn't just theory. They ran experiments with art, treated patients,
- 2:09Speaker 1: and saw high reactivation rates.
- 2:11Speaker 2: That's wild when you look at the raw numbers. But
- 2:14Speaker 2: doesn't this also open up a can of worms in
- 2:17Speaker 2: terms of safety and efficacy?
- 2:19Speaker 1: Absolutely. The safety and feasibility of targeting these proteins are
- 2:23Speaker 1: key concerns. We need to understand the full scope of
- 2:26Speaker 1: the molecular mechanisms involved and ensure that any therapies don't
- 2:30Speaker 1: have unintended side effects. But the potential benefits are huge.
- 2:35Speaker 1: If this works, we might be closer to finding a cure.
- 2:38Speaker 2: And it's not just about HIV either. BRD4S role in
- 2:42Speaker 2: cancer research could mean that these insights might have applications
- 2:45Speaker 2: beyond just viral diseases. It's about making our therapeutic strategies
- 2:49Speaker 2: more precise and targeted.
- 2:51Speaker 1: Right, exactly. So, the future outlook here is promising. But
- 2:56Speaker 1: we have got a long road ahead. More research will
- 2:59Speaker 1: be needed to confirm the safety and effectiveness of these approaches.
- 3:04Speaker 1: But for now, this opens up exciting possibilities. So, let's
- 3:08Speaker 1: dive into how these specific proteins, NL, USP7, and BRD4,
- 3:14Speaker 1: are crucial in keeping HIV dormant within our bodies. Think
- 3:19Speaker 1: of them as the virus' hidden shields, protecting it from detection.
- 3:24Speaker 2: Exactly. And it's like the virus is hiding in a cave,
- 3:28Speaker 2: and NLUSP7 and Briardy4 are the stalactites and stalagmites, keeping
- 3:35Speaker 2: the virus secure. By disrupting these structures, we potentially expose
- 3:40Speaker 2: the virus to the light of our drugs.
- 3:42Speaker 1: Right. NL, for instance. works by binding to the HIV
- 3:46Speaker 1: genome and stabilizing it, which keeps the virus in a
- 3:49Speaker 1: dormant state. It's like having a lock on a safe
- 3:52Speaker 1: that prevents anything from accessing the contents.
- 3:55Speaker 2: And USP7 plays its role too. It's known to do
- 3:58Speaker 2: ubiquitinate proteins, which can affect the viral replication cycle. Without it,
- 4:04Speaker 2: the virus might not be able to replicate properly, making
- 4:07Speaker 2: it more susceptible to our therapies. True.
- 4:09Speaker 1: And BRD4, on the other hand, is a master controller.
- 4:14Speaker 1: It's involved in the recruitment of proteins needed for HIV transcription.
- 4:20Speaker 1: By blocking BRD4, we could essentially prevent the virus from
- 4:24Speaker 1: turning on and causing new infections.
- 4:27Speaker 2: Exactly. But here is the tricky part. Disrupting these pathways
- 4:31Speaker 2: could lead to unintended consequences. For example, if we target
- 4:36Speaker 2: BRD4 too broadly, we risk affecting other important cellular functions
- 4:41Speaker 2: that rely on it.
- 4:42Speaker 1: That's a valid concern. We need to find a fine line,
- 4:46Speaker 1: like Goldilocks, finding the perfect porridge. Too little, and the
- 4:50Speaker 1: virus might stay latent. Too much, and we could destabilize
- 4:54Speaker 1: other essential biological processes.
- 4:56Speaker 2: And that's why the research is so exciting. It's not
- 5:00Speaker 2: just about finding a single pathway but understanding how each
- 5:04Speaker 2: protein interacts with the others. This complexity means that future
- 5:08Speaker 2: therapies might need to be tailor-made to target these proteins
- 5:11Speaker 2: in a safe and effective way. Right.
- 5:14Speaker 1: But the potential benefits are enormous. If we can develop
- 5:18Speaker 1: drugs that specifically target ENL, USP7, and BRD4, we could
- 5:24Speaker 1: significantly reduce the size of the HIV reservoirs, moving us
- 5:28Speaker 1: closer to a functional cure.
- 5:30Speaker 2: Absolutely. It's all about precision medicine. By targeting these specific proteins,
- 5:36Speaker 2: we can try to reactivate and eliminate HIV while minimizing
- 5:40Speaker 2: the risk of side effects. that's the ultimate goal isn't.
- 5:44Speaker 1: It exactly and this research opens up new avenues not
- 5:48Speaker 1: just for hiv but also for other persistent viral infections
- 5:53Speaker 1: it's a leap forward that could have far-reaching implications for
- 5:57Speaker 1: global health so as we understand it targeting nl and
- 6:01Speaker 1: usp7 can potentially reactivate latent hiv but what are the
- 6:05Speaker 1: real risks we need to be wary of for instance
- 6:09Speaker 1: Can these proteins be targeted without causing undue harm to patients?
- 6:13Speaker 2: Right, that's a critical question. A major risk, as hinted
- 6:17Speaker 2: in the study, is the potential side effects. For example,
- 6:21Speaker 2: disrupting these proteins might cause unintended activation of other pathways,
- 6:26Speaker 2: potentially leading to increased viral load or even other health issues.
- 6:30Speaker 2: It's a delicate balance.
- 6:31Speaker 1: Exactly. Which brings up an interesting contradiction. On one hand,
- 6:36Speaker 1: targeting ENL and USP7 could be a game changer for
- 6:41Speaker 1: latent HIV, but on the other, to raise the risk
- 6:44Speaker 1: of collateral damage. How do we navigate those risks?
- 6:47Speaker 2: The study points to the need for precise targeting. The
- 6:51Speaker 2: mechanism by which ENL and USP7 stabilize BAR-D4 is akin
- 6:56Speaker 2: to the virus hiding in a fortified bunker. If we
- 6:59Speaker 2: disrupt just the right part of the bunker, we might
- 7:02Speaker 2: not trigger a massive flood of virus into the bloodstream. Instead,
- 7:06Speaker 2: We target it selectively.
- 7:07Speaker 1: That's wild when you look at the raw numbers. The
- 7:10Speaker 1: experiment demonstrated high reactivation rates, but can we extrapolate that
- 7:15Speaker 1: to clinical settings without unforeseen issues? The study highlights the
- 7:20Speaker 1: importance of safety.
- 7:21Speaker 2: Absolutely. Safety trials will be essential. One key concern is
- 7:26Speaker 2: the potential for drug toxicity. We need to ensure that
- 7:29Speaker 2: the treatment doesn't cause more harm than good. To raise
- 7:32Speaker 2: also the issue of patient selection some, might be more
- 7:35Speaker 2: susceptible than others due to their specific immune profiles.
- 7:39Speaker 1: Right, and this ties in nicely with the broader implications.
- 7:43Speaker 1: If successful, could this not only impact HIV research, but
- 7:47Speaker 1: also cancer therapy, given the overlap in mechanisms?
- 7:51Speaker 2: Precisely. The BRD4 protein's involvement in both conditions suggests a
- 7:56Speaker 2: potential cross, pollination of therapies. However, the challenges in delivering
- 8:01Speaker 2: a safe and effective treatment are daunting. We need to
- 8:05Speaker 2: address not just the technical aspects, but also the regulatory
- 8:08Speaker 2: and ethical considerations.
- 8:10Speaker 1: Speaking of which, the potential benefits are clear. A functional
- 8:14Speaker 1: cure for HIV could revolutionize global health. But we must
- 8:17Speaker 1: tread cautiously. The path from lab to clinic is fraught
- 8:20Speaker 1: with obstacles, and every step must be meticulously considered.
- 8:24Speaker 2: Absolutely. The next phases of research must focus on refining
- 8:28Speaker 2: the mechanisms and ensuring the treatment is both safe and effective.
- 8:33Speaker 2: It's a race against time, but with careful planning, we
- 8:36Speaker 2: might just turn a corner in the fight against HIV.
- 8:39Speaker 1: The journey from scientific discovery to practical application is never straightforward. Take,
- 8:45Speaker 1: for instance, the ENL-USP7 and BRD4 pathway. A recent study
- 8:51Speaker 1: showed that disrupting these protein interactions could reactivate latent HIV.
- 8:57Speaker 1: But the devil is in the details. What exactly are
- 9:00Speaker 1: the mechanistic insights? that need further exploration.
- 9:04Speaker 2: Precisely. For instance, the exact nature of how these proteins
- 9:08Speaker 2: stabilize the HIV-bar T4 protein is still a bit of
- 9:12Speaker 2: a mystery. It's like finding the molecular lock and key,
- 9:16Speaker 2: but not yet fully understanding the lock's mechanism. And this
- 9:20Speaker 2: is crucial because we need to ensure that targeting these
- 9:23Speaker 2: pathways doesn't have unintended side effects.
- 9:26Speaker 1: Exactly. Like the old saying goes, knowledge is power, but
- 9:30Speaker 1: insight is the key to unlock that power. Let's dive deeper, then.
- 9:34Speaker 1: How do we move from a hypothesis to a robust
- 9:37Speaker 1: clinical trial with minimal risks? Right.
- 9:40Speaker 2: And that's where the collaborative efforts come into play. We
- 9:43Speaker 2: need multidisciplinary teams, including virologists, immunologists, and clinical researchers, all
- 9:50Speaker 2: working together. It's not just about the science, but also
- 9:53Speaker 2: about managing expectations and securing funding, which can be a barrier.
- 9:58Speaker 1: Absolutely true. The timeline for moving from lab bench to
- 10:01Speaker 1: patient table is fraught with delays. You know, even with
- 10:05Speaker 1: all the advancements in gene editing and targeted therapies, the
- 10:09Speaker 1: real world can be a different story. We need to
- 10:12Speaker 1: set realistic goals and be ready for the twists and
- 10:15Speaker 1: turns along the way.
- 10:16Speaker 2: Wait, but how does that actually play out in practice?
- 10:20Speaker 2: For example, think about the phase I trials focusing on
- 10:24Speaker 2: safety and toxicity. They need to be meticulously planned to
- 10:28Speaker 2: ensure the treatment is both effective and safe.
- 10:31Speaker 1: Right on. Another challenge is the variability in how latent
- 10:35Speaker 1: HIV reservoirs are established. Each patient might have a different profile,
- 10:40Speaker 1: so one-size-fits-all solutions might not work. Personalized medicine is key here.
- 10:47Speaker 1: but it requires a lot of data and analytical power
- 10:50Speaker 1: to tailor treatments effectively.
- 10:51Speaker 2: Exactly personalized medicine, and let's not forget the ethical considerations.
- 10:57Speaker 2: With such powerful tools to raise a risk of exacerbating
- 11:00Speaker 2: healthcare disparities, we need to address these issues head-on to
- 11:04Speaker 2: ensure equitable access to new treatments.
- 11:06Speaker 1: That's a crucial point. The landscape of HIV research and
- 11:10Speaker 1: treatment is complex, with layers of scientific, ethical, and regulatory challenges.
- 11:16Speaker 1: We need a cohesive strategy to navigate through these layers,
- 11:19Speaker 1: ensuring that our advancements benefit everyone, not just a select few.
- 11:23Speaker 2: Right, and that's where the community engagement comes in. We
- 11:27Speaker 2: need to involve patients, advocates, and policymakers early on to
- 11:31Speaker 2: build trust and support. It's a collaborative effort that requires
- 11:34Speaker 2: everyone's voice to be heard.
- 11:36Speaker 1: So, thinking ahead, the implications of this research don't just
- 11:40Speaker 1: lie in the treatment of HIV. We are talking about
- 11:44Speaker 1: a potential paradigm shift. That's exactly right.
- 11:53Speaker 2: The broader application to cancer therapy is pretty tantalizing. The
- 11:58Speaker 2: way these protein pathways stabilize the latent HIV state through
- 12:02Speaker 2: similar mechanisms to how they might operate in certain cancers
- 12:05Speaker 2: could mean that our cure approach for HIV might also
- 12:08Speaker 2: serve as a model for targeted therapies in oncology.
- 12:12Speaker 1: Absolutely. It's not just about moving from a state of
- 12:15Speaker 1: latent to active HIV. We are talking about a fundamental
- 12:19Speaker 1: understanding of how these proteins modulate gene expression in both settings.
- 12:23Speaker 1: The key could be in developing drugs that target these
- 12:26Speaker 1: pathways without wreaking havoc on the immune system, which is
- 12:30Speaker 1: always a fine line.
- 12:32Speaker 2: Yes, and we need to carefully consider the broader implications.
- 12:35Speaker 2: While the goal is to maximize the safety of the patient,
- 12:39Speaker 2: we must also factor in the economic and social dimensions.
- 12:42Speaker 2: The cost of developing and implementing these drugs could be prohibitive,
- 12:46Speaker 2: which means access is still a big issue.
- 12:48Speaker 1: Definitely. Let's touch on that for a moment. The community
- 12:52Speaker 1: engagement we discussed earlier is crucial. We need to ensure
- 12:56Speaker 1: that the voices from the community, especially those most affected,
- 13:00Speaker 1: are at the forefront when we plan these interventions. It's
- 13:03Speaker 1: about building trust and ensuring equitable access.
- 13:06Speaker 2: Right, and that's why involving stakeholders like patients, advocates, and
- 13:11Speaker 2: policymakers from the start is so important. It's not just
- 13:15Speaker 2: about the science, it's about navigating the complex landscape of
- 13:18Speaker 2: healthcare equity.
- 13:19Speaker 1: Exactly. We also need to continue pushing for more comprehensive
- 13:23Speaker 1: research to understand the full mechanisms. While these initial findings
- 13:27Speaker 1: are promising, they only scratch the surface. To read still
- 13:30Speaker 1: so much we need to learn about the interactions between ENL, USP7,
- 13:35Speaker 1: and BRD4. especially in different contexts like the brain.
- 13:38Speaker 2: And the regulatory landscape isn't exactly a walk in the park.
- 13:42Speaker 2: Clinical validation and safety trials will require rigorous testing. But
- 13:47Speaker 2: if all goes well, this could be a game changer.
- 13:50Speaker 1: Indeed. So, in summary, while the road ahead is challenging,
- 13:54Speaker 1: the potential benefits are huge. We are looking at a
- 13:57Speaker 1: step toward a cure for HIV and possibly other persistent
- 14:00Speaker 1: viral infections, and even cancer. It's a complex and multifaceted journey.
- 14:06Speaker 1: but one that holds immense promise. That brings us to
- 14:09Speaker 1: the end of today's episode. Thank you so much for
- 14:12Speaker 1: spending part of your day with me. If you found
- 14:14Speaker 1: this episode's tips helpful and want to make sure you
- 14:17Speaker 1: don't miss the next conversation, please take a quick second
- 14:20Speaker 1: to hit that subscribe or follow button on whatever platform
- 14:24Speaker 1: you are listening on. It's a completely free way to
- 14:27Speaker 1: support the show and helps more people find us. This
- 14:30Speaker 1: podcast is independently produced, so if you are ever in
- 14:33Speaker 1: a position where you would like to help keep it running,
- 14:36Speaker 1: We do accept small donations. You can find a link
- 14:39Speaker 1: right in the episode description below to buy us a
- 14:41Speaker 1: coffee or contribute what you can. Every bit genuinely helps.
- 14:46Speaker 1: Take care of yourself, stay balanced, and we will talk
- 14:49Speaker 1: again soon.